254 related articles for article (PubMed ID: 29957723)
1. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
2. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
[TBL] [Abstract][Full Text] [Related]
3. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
[TBL] [Abstract][Full Text] [Related]
4. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
[TBL] [Abstract][Full Text] [Related]
5. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
7. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.
Duby Z; Katz AWK; Browne EN; Mutero P; Etima J; Zimba CC; Woeber K; Atujuna M; Reddy K; van der Straten A;
AIDS Behav; 2020 Feb; 24(2):617-628. PubMed ID: 31030301
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
[TBL] [Abstract][Full Text] [Related]
9. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
[TBL] [Abstract][Full Text] [Related]
10. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
11. Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe.
Stoner MCD; Mathebula F; Sedze N; Seyama L; Mohuba R; Fabiano Z; Etima J; Young A; Scheckter R; van der Straten A; Piper J; Noguchi L; Montgomery ET; Balán IC
AIDS Behav; 2024 Jul; 28(7):2264-2275. PubMed ID: 38526641
[TBL] [Abstract][Full Text] [Related]
12. Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.
Montgomery ET; Katz AWK; Duby Z; Mansoor LE; Morar NS; Naidoo K; Tsidya M; Chitukuta M; Guma V; Tenza S; Leslie J; Garcia M; Naidoo S
AIDS Behav; 2021 Jun; 25(6):1890-1900. PubMed ID: 33389318
[TBL] [Abstract][Full Text] [Related]
13. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
14. First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
van der Straten A; Browne EN; Shapley-Quinn MK; Brown ER; Reddy K; Scheckter R; Soto-Torres L; Palanee-Phillips T; Baeten JM; Mensch B;
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):304-310. PubMed ID: 30844995
[TBL] [Abstract][Full Text] [Related]
15. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
16. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
18. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
19. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
Leslie J; Kiweewa F; Palanee-Phillips T; Bunge K; Mhlanga F; Kamira B; Baeten J; Katz A; Hillier S; Montgomery E;
BMC Womens Health; 2021 Apr; 21(1):175. PubMed ID: 33892693
[TBL] [Abstract][Full Text] [Related]
20. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa.
Chitukuta M; Duby Z; Katz A; Nakyanzi T; Reddy K; Palanee-Phillips T; Tembo T; Etima J; Musara P; Mgodi NM; van der Straten A;
Cult Health Sex; 2019 Nov; 21(11):1209-1224. PubMed ID: 30657023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
